Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501353 | 0.91 | ROCK2 (0.44) | ROCK2ROCK1NAMPTMYLK4GAA | |
| SCHEMBL30744162 | 0.91 | ROCK2 (0.44) | ROCK2ROCK1NAMPTMYLK4GAA | |
| SCHEMBL23501355 | 0.91 | ROCK2 (0.44) | ROCK2ROCK1NAMPTMYLK4GAA | |
| SCHEMBL30002705 | 0.90 | ALDH1A1 (0.38) | ROCK2ROCK1NAMPTMYLK4ALDH1A1 | |
| SCHEMBL23501189 | 0.90 | ROCK2 (0.37) | ROCK2ROCK1NAMPTMYLK4GAA | |
| SCHEMBL30744188 | 0.90 | ROCK2 (0.37) | ROCK2ROCK1NAMPTMYLK4GAA | |
| SCHEMBL23501190 | 0.90 | ROCK2 (0.37) | ROCK2ROCK1NAMPTMYLK4GAA | |
| SCHEMBL30744200 | 0.90 | ROCK2 (0.37) | ROCK2ROCK1NAMPTMYLK4GAA | |
| SCHEMBL28573833 | 0.90 | ROCK2 (0.38) | ROCK2ROCK1ALDH1A1MEN1GAA | |
| SCHEMBL23501411 | 0.89 | ROCK2 (0.43) | ROCK2ROCK1ALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | ROCK2 3/4885ROCK1 1/4885NAMPT 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.